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Introduction
 
These FAQs on hepatitis have been 
produced by the Local Government 
Association (LGA) and Public Health 
England (PHE) to address questions that 
councillors may have on hepatitis and the 
viruses that cause it. 
What is viral hepatitis? 
Hepatitis is inflammation of the liver and 
can be caused by toxic or infectious agents. 
Viral hepatitis can be caused by a number of 
different hepatitis viruses of which A, B and 
C are among the commonest. These viruses 
differ in key features which affect diagnosis, 
prevention and control. This document 
focuses on hepatitis B and C because both 
viruses can persist in the liver for many 
years (so called “chronic infection”). Chronic 
infection can cause liver damage and, after 
many years, lead to liver failure and liver 
cancer in around 15 per cent to 25 per cent 
of infected individuals. 
Symptoms and signs 
Any type of viral hepatitis presents with the
same symptoms - fatigue, jaundice, loss of
appetite, nausea, vomiting, abdominal pain and
joint pains. However for hepatitis B and C more
than 70 per cent of adults have no symptoms
at all at the time of becoming infected.
Chronic liver disease can also remain silent 
for many years. Unless detected by a blood 
test, patients may first present very late 
with signs of liver failure, including jaundice, 
swelling of the abdomen, confusion and or 
vomiting blood. 
Which groups of the 
population are most affected? 
Most people with chronic hepatitis B in the 
UK acquired infection at birth or during 
childhood overseas. Therefore, most severe 
complications from hepatitis B in the UK 
occur in migrant populations, particularly 
those born in Africa and Asia. Common risk 
groups for acquiring the infection in the UK 
include those who have multiple sexual 
partners or those who inject drugs. 
In contrast, most chronic hepatitis C 
infections are seen in people who have 
injected drugs in the UK. The prevalence 
of hepatitis C is also slightly higher in 
those born and raised in certain countries 
(including many in the Middle East and Asia), 
and in those who received blood products 
or blood transfusions in the UK before the 
introduction of virus inactivation and 
donor screening. 
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The essentials of hepatitis B and C
	
Hepatitis B virus Hepatitis C virus 
Routes of transmission Exposure to infectious 
blood or body fluids 
contaminated with blood 
at the time of birth, during 
sexual intercourse, or from 
contaminated needles 
Exposure to infectious blood 
or body fluids contaminated 
with blood, mainly from 
contaminated needles during 
injecting drug use or medical 
treatment 
Incubation period 45 to 160 days (average 
120 days) 
14-180 days (average 
45 days) 
Likelihood of developing 
symptoms of acute 
infection 
Depends on age at time of 
infection:
• <1% of infants 
• 5%-15% of children aged 
1-5 years 
• 30-50% of over 5 years 
<10% of newly infected 
persons 
Estimated number of 
adults with chronic 
infection in England 
120,000 chronically infected 
adults 
160,000 chronically infected 
adults 
Screening (blood test) • All pregnant women • People who have ever 
recommendations for • Babies born to mothers injected drugs. 
chronic infection infected with hepatitis B 
• Adults and children at 
increased risk of infection, 
particularly migrants from 
medium or high 
prevalence countries and 
people who inject or have 
injected drugs. 
• People who received a 
blood transfusion before 
1991 or blood products 
before 1986, when 
screening of blood donors 
for hepatitis C infection, or 
inactivation of viruses 
were introduced. 
• People born or brought 
up in a country with high 
or intermediate rates of 
chronic hepatitis C. 
• Babies born to mothers 
infected with hepatitis C. 
• Prisoners, including young
offenders. 
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• Looked-after children and 
young people, including 
those living in care homes. 
• People living in hostels for 
the homeless or sleeping 
on the streets. 
• HIV-positive men who 
have sex with men. 
• Close contacts of 
someone known to be 
chronically infected with 
hepatitis C. 
Where to get tested and / • Antenatal clinic • GP 
or vaccinated • GP
• GUM/STI clinic 
• Drug treatment service 
• GUM/STI clinic 
• Drug treatment service 
Treatment NICE recommended anti-
viral therapies 
NICE recommended anti-
viral therapies with good 
cure rate 
How can we prevent 
hepatitis? 
Effective vaccines against hepatitis B are
available and recommended for individuals
at risk. Hepatitis B vaccine is currently
recommended for the following groups of the
population: 
• babies born to mothers infected with 
hepatitis B 
• close family and household 	contacts of a 
person with chronic hepatitis B infection 
• injecting drug users (and sexual contacts 
or children of injectors) 
• men who have sex with men. 
• individuals who change sexual partners 
frequently 
• certain occupations: e.g. healthcare 
workers 
• families adopting children from countries 
with high or intermediate rates of hepatitis B 
• foster carers 
•		 individuals receiving regular blood or blood 
products and their carers 
• patients with chronic liver disease including 
hepatitis C-infected persons 
• patients with chronic kidney failure 
• persons with HIV infection 
•		prison inmates 
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•		 individuals in residential accommodation 
for those with learning difficulties 
•		people travelling to or going to reside in 
areas with high or intermediate rates of 
hepatitis B 
•		 individuals at occupational risk, e.g. 
healthcare workers, laboratory staff, staff at 
residential accommodation for those with 
learning difficulties. 
There is no vaccine against hepatitis C 
infection, but spread of both hepatitis B and 
C viruses can be reduced by preventing 
exposure to blood and body fluids from 
infected individuals. 
In the health care setting, transmission 
of infection is prevented by following 
appropriate precautions to avoid 
contamination of needles and other sharp 
instruments, and by screening blood, tissue 
and organs for donation. 
In the community, prevention of infection in 
people who inject drugs depends on three 
elements: reducing initiation of injecting 
drug use, helping people to stop injecting 
and promoting safer injecting practice 
(for example by provision of clean needles 
and syringes). 
What are the barriers 
to hepatitis prevention 
and control? 
Uptake of screening and vaccination is a 
challenge because: 
•		Cultural and language barriers may hinder 
access to services for people with chronic 
hepatitis B and C who are from ethnically 
diverse populations 
• People may not be aware that they are at 
risk or be reluctant to admit that they have 
a history of high risk behaviour, such as 
injecting drug use 
• Clinicians may not be aware or may forget 
to offer vaccination and screening to high 
risk individuals such as those who inject 
drugs or infants and household contacts of 
a hepatitis B positive mum. 
Overcoming barriers to screening and 
vaccination by raising both professional and 
public awareness and offering accessible 
services is a critical component of reducing 
the burden of undiagnosed infection. Most 
people at risk of or already infected with 
hepatitis B and C are from under-served 
communities in which inequalities in 
health access and outcomes exist. These 
populations include ethnically diverse migrant 
populations and socially excluded groups 
such as inmates and young offenders, 
current or past injecting drug users. 
How can we treat 
chronic hepatitis? 
Antiviral treatments for both hepatitis B 
and C are available and recommended by 
the National Institute for Health and Care 
Excellence (NICE). For hepatitis C, a high 
proportion of patients treated will clear 
infection for good, particularly if therapy is 
started early. Treatments is not cheap but is 
considered cost-effective as the cost of not 
treating infection can be high in the longer 
term. Hepatitis C related hospital admissions, 
registrations for liver transplants and deaths 
from hepatitis end-stage liver disease and 
liver cancer continue to rise in England. 
Despite effective treatment it is estimated 
that only 3 per cent of those with chronic 
hepatitis C get treated each year; the figure 
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for hepatitis B is not known. Some of the 
major challenges to treatment of hepatitis B 
and C include: 
•		People do not get diagnosed, because 
they do not consider themselves to be 
at risk. 
• Individuals who have been diagnosed with 
chronic hepatitis B or C infection find it 
difficult to adhere to the months or years 
of treatment, sometimes with unpleasant 
side effects 
• Many of the individuals affected by 
hepatitis C are from marginalised 
populations, for example, people who 
inject drugs and the prison population, who 
often find it difficult to access treatment in 
specialist hospital settings 
What can local authorities do? 
• Through overview and scrutiny committees 
and health and wellbeing boards, local 
authorities are in a strong position to drive 
improvements in uptake of screening, 
vaccination and treatment of hepatitis, 
which will also help delivery against 
health inequalities, liver disease and 
immunisation public health outcome 
measures. Local authorities can: 
• Undertake joint audits with NHS 
commissioners to assess hepatitis B and 
C needs and services in their community 
and develop targeted measures for 
reducing transmission and improving 
treatment uptake 
•		 Ensure that structures and policies are in place
to provide vaccination and monitor vaccine
uptake in people who are considered high risk
and eligible for hepatitis B vaccination, taking
into account the plurality and complexity of
provision of immunisation services. 
• Ask whether screening, immunisation and 
treatment services reach out to diverse 
populations and are accessible to deprived 
or marginalised sections of the population. 
• Influence commissioning of hepatitis 
screening and vaccination for people who 
use sexual health, genitourinary medicine / 
STI clinics and drug treatment services. 
•		Develop strategic partnerships to deliver 
hepatitis C treatment through integrated 
care pathways in non-conventional 
settings, such as drug services, prisons or 
primary care. 
•		Hold the NHS and stakeholders to 
account on viral hepatitis, and ensure 
that all people with hepatitis B and C 
are supported by public health and 
NHS services. 
Models of good practice 
Integrated Care for Hepatitis C in Drug 
Users –Stoke on Trent Community 
Viral Hepatitis Service 
An integrated hepatitis C treatment
service in Stoke on Trent provided by 
a charity (CRIS) with links to a local
hepatologist, has had a high uptake of 
treatment and cure rate amongst this
client group since its launch two years 
ago. Of the 282 clients known to drug 
services who were newly diagnosed
with hepatitis C, 262 were referred for
assessment and treatment; of these 25
were deemed either unsuitable or dropped
out (in stark contrast to most hospital-
based services). Of the 262 engaged
clients, 148 (56 per cent) commenced 
treatment and 100 (38 per cent) were 
cured after treatment completion. 
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Greater London Authority to tackle 
health inequalities in ‘the capital of 
hepatitis C’ 
An estimated 23,000 people 
with hepatitis C in London are 
undiagnosed. In March 2013 the 
Greater London Authority (GLA) 
convened a group of experts to look at 
hepatitis C and its associated health 
inequalities in London. The roundtable 
event brought together senior 
stakeholders from the NHS, local 
authorities and the voluntary sector 
to discuss developing an effective 
response in the capital. During the 
event it was agreed that a steering 
group of stakeholders would meet 
again to devise an action plan on how 
to effectively address hepatitis C 
in London. 
Resources 
World Hepatitis Day http://www. 
worldhepatitisalliance.org/en/home.html 
Immunisation against infectious disease: the 
Green Book. https://www.gov.uk/government/ 
organisations/public-health-england/series/ 
immunisation-against-infectious-disease-the-
green-book 
NICE public health guidance.PH 43 Hepatitis 
B and C: ways to promote and offer testing 
to people at increased risk of infection. 
December 2012. http://publications.nice.org. 
uk/hepatitis-b-and-c-ways-to-promote-and-
offer-testing-to-people-at-increased-risk-of-
infection-ph43/recommendations#whose-
health-will-benefit 
Capital Challenge – Tackling hepatitis C in 
London available from the Hepatitis C Trust  
http://www.hepctrust.org.uk/News_Resources/ 
news/2013/March/Greater+London+Authority 
+to+tackle+health+inequalities+in+%e2%80% 
98the+capital+of+hepatitis+C%e2%80%99 
Hepatitis B antenatal screening and newborn 
immunisation programme: Best practice 
guidance https://www.gov.uk/government/ 
publications/hepatitis-b-antenatal-screening-
and-newborn-immunisation-programme-best-
practice-guidance 
Blood borne infections: Good practice 
examples from front line Services. Blood 
Borne Infections Symposium, June 21 2013. 
Public Health England 
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